163 related articles for article (PubMed ID: 30860874)
1. Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms.
Koshibu M; Mori Y; Saito T; Kushima H; Hiromura M; Terasaki M; Takada M; Fukui T; Hirano T
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E895-E907. PubMed ID: 30860874
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
Jojima T; Uchida K; Akimoto K; Tomotsune T; Yanagi K; Iijima T; Suzuki K; Kasai K; Aso Y
Atherosclerosis; 2017 Jun; 261():44-51. PubMed ID: 28445811
[TBL] [Abstract][Full Text] [Related]
3. The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis.
Kushima H; Mori Y; Koshibu M; Hiromura M; Kohashi K; Terasaki M; Fukui T; Hirano T
Cardiovasc Diabetol; 2017 Oct; 16(1):122. PubMed ID: 28969637
[TBL] [Abstract][Full Text] [Related]
4. Insulin decreases atherosclerotic plaque burden and increases plaque stability via nitric oxide synthase in apolipoprotein E-null mice.
Mori Y; Chiang S; Bendeck MP; Giacca A
Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E335-45. PubMed ID: 27221119
[TBL] [Abstract][Full Text] [Related]
5. Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice.
Lu J; Xiang G; Liu M; Mei W; Xiang L; Dong J
Atherosclerosis; 2015 Dec; 243(2):438-48. PubMed ID: 26520898
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.
Bruen R; Curley S; Kajani S; Lynch G; O'Reilly ME; Dillon ET; Brennan EP; Barry M; Sheehan S; McGillicuddy FC; Belton O
J Pharmacol Exp Ther; 2019 Sep; 370(3):447-458. PubMed ID: 31270216
[TBL] [Abstract][Full Text] [Related]
7. AMPKα inactivation destabilizes atherosclerotic plaque in streptozotocin-induced diabetic mice through AP-2α/miRNA-124 axis.
Liang WJ; Zhou SN; Shan MR; Wang XQ; Zhang M; Chen Y; Zhang Y; Wang SX; Guo T
J Mol Med (Berl); 2018 May; 96(5):403-412. PubMed ID: 29502204
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice.
Li P; Tang Z; Wang L; Feng B
Mol Med Rep; 2017 Sep; 16(3):3421-3426. PubMed ID: 28713911
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway.
Ke J; Liu Y; Yang J; Lu R; Tian Q; Hou W; Wang G; Wei R; Hong T
Sci Rep; 2017 Feb; 7():41085. PubMed ID: 28145471
[TBL] [Abstract][Full Text] [Related]
10. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.
Gaspari T; Welungoda I; Widdop RE; Simpson RW; Dear AE
Diab Vasc Dis Res; 2013 Jul; 10(4):353-60. PubMed ID: 23673376
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats.
Inoue T; Inoguchi T; Sonoda N; Hendarto H; Makimura H; Sasaki S; Yokomizo H; Fujimura Y; Miura D; Takayanagi R
Atherosclerosis; 2015 May; 240(1):250-9. PubMed ID: 25818251
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide ameliorates cognitive decline by promoting autophagy via the AMP-activated protein kinase/mammalian target of rapamycin pathway in a streptozotocin-induced mouse model of diabetes.
Kong FJ; Wu JH; Sun SY; Ma LL; Zhou JQ
Neuropharmacology; 2018 Mar; 131():316-325. PubMed ID: 29305122
[TBL] [Abstract][Full Text] [Related]
13. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2.
Wang Q; Zhang M; Liang B; Shirwany N; Zhu Y; Zou MH
PLoS One; 2011; 6(9):e25436. PubMed ID: 21980456
[TBL] [Abstract][Full Text] [Related]
14. Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.
Bruen R; Curley S; Kajani S; Crean D; O'Reilly ME; Lucitt MB; Godson CG; McGillicuddy FC; Belton O
Cardiovasc Diabetol; 2017 Nov; 16(1):143. PubMed ID: 29110715
[TBL] [Abstract][Full Text] [Related]
15. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.
Tang ST; Su H; Zhang Q; Tang HQ; Wang CJ; Zhou Q; Wei W; Zhu HQ; Wang Y
Int J Mol Med; 2016 Jun; 37(6):1558-66. PubMed ID: 27122056
[TBL] [Abstract][Full Text] [Related]
16. Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase.
Seneviratne A; Cave L; Hyde G; Moestrup SK; Carling D; Mason JC; Haskard DO; Boyle JJ
Cardiovasc Res; 2021 Apr; 117(5):1295-1308. PubMed ID: 32667970
[TBL] [Abstract][Full Text] [Related]
17. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
Gaspari T; Liu H; Welungoda I; Hu Y; Widdop RE; Knudsen LB; Simpson RW; Dear AE
Diab Vasc Dis Res; 2011 Apr; 8(2):117-24. PubMed ID: 21562063
[TBL] [Abstract][Full Text] [Related]
18. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.
Tashiro Y; Sato K; Watanabe T; Nohtomi K; Terasaki M; Nagashima M; Hirano T
Peptides; 2014 Apr; 54():19-26. PubMed ID: 24418070
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide regulates lipid metabolism via FGF21- LKB1- AMPK- ACC1 pathway in white adipose tissues and macrophage of type 2 diabetic mice.
Zhang N; Liu C; Zhang Y; Xu D; Gui L; Lu Y; Zhang Q
Biochem Biophys Res Commun; 2021 Apr; 548():120-126. PubMed ID: 33640604
[TBL] [Abstract][Full Text] [Related]
20. Plaque-targeted, proteolysis-resistant, activatable and MRI-visible nano-GLP-1 receptor agonist targets smooth muscle cell differentiation in atherosclerosis.
Maiseyeu A; Di L; Ravodina A; Barajas-Espinosa A; Sakamoto A; Chaplin A; Zhong J; Gao H; Mignery M; Narula N; Finn AV; Rajagopalan S
Theranostics; 2022; 12(6):2741-2757. PubMed ID: 35401813
[No Abstract] [Full Text] [Related]
[Next] [New Search]
